Nov 5, 2024 · Background: Anitocabtagene autoleucel (anito-cel, previously CART-ddBCMA) is an autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy with a novel D-domain binder under development for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).

May 9, 2024 · Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year.

May 14, 2024 · Arcellx and Kite Pharma are planning to launch a Phase 3 clinical trial, dubbed iMMagine-3, to test their cell therapy anitocabtagene autoleucel (anito-cel) in people with hard-to-treat multiple myeloma.

Sep 30, 2024 · Treatment with the BCMA-directed CAR T-cell therapy anitocabtagene autoleucel (anito-cel; CART-ddBCMA) led to an overall response rate (ORR) of 100% in patients with relapsed or refractory...

Anito-cel Phase 1 Results: Background and Methods Phase 1 first-in-human trial is in patients with relapsed and/or refractory myeloma •Prior IMiD, PI, and CD38-targeted therapy •Received ≥3 prior lines of therapies or triple refractory 2 Dose Levels evaluated, 6 patients in each dose escalation cohort •DL1 = 100 + 20% x 106 CAR+ cells

Jan 6, 2025 · Anitocabtagene autoleucel (anito-cel) produced durable responses and displayed a manageable safety profile in patients with relapsed/refractory multiple myeloma who received at least 3 prior...

May 14, 2024 · Anito-cel is an BCMA CAR T investigational that utilizes a novel binder (or CAR) known as the D-Domain. Its small size (8kDa) facilitates high T-cell transduction and expression, resulting in more CAR positive cells and more CARs expressed per T-cell.

Anitocabtagene autoleucel (anito-cel, previously CART-ddBCMA) is an autologous D-Domain BCMA-directed chimeric antigen receptor (CAR) T-cell therapy being studied in patients with RRMM. 73 amino acids that fold into a stable triple alpha-helix bundle, resulting in several key attributes described in Figure 15,6. RRMM.

Dec 10, 2024 · Anito-cel is a developmental CAR T therapy designed to target BCMA, a cell surface protein highly expressed on malignant plasma cells. Last month, Gilead and Arcellx touted the best-in-class potential of anito-cel in a data preview, disclosing a 95% overall response rate and a 92% minimal residual disease rate.

Arcellx’s anitocabtagene autoleucel (anito-cel) is the first BCMA CAR T to be investigated in multiple myeloma that utilizes our novel and compact D-Domain binder.